Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

GMOs

- PMLiVE

Sanofi and GSK share positive data for two COVID-19 booster vaccine trials

Both the COVIBOOST and phase 3 VAT02 trials showed the booster was well-tolerated, with favourable safety profiles

- PMLiVE

Sanofi and GSK share positive data for two COVID-19 booster vaccine trials

Both the COVIBOOST and phase 3 VAT02 trials showed the booster was well-tolerated, with favourable safety profiles

The Future of MedTech: Streamlined Clinical Data Collection & Management

Jón Ingi Bergsteinsson, Co-founder & CCO at SMART-TRIAL, explores the barriers to, and benefits of, digitalization of clinical operations and trials in the MedTech industry, plus much more!

Impetus Digital

- PMLiVE

Moderna announces trial results for new COVID-19 booster vaccine candidate

The new vaccine candidate offers nearly twice as much protection against Omicron as Spikevax

- PMLiVE

Pfizer to expand Paxlovid manufacturing in US to meet global demand

The $120m investment will also create more than 250 high-skilled manufacturing jobs

Engaging Patients “Just-In-Time” with Machine Learning

Omri Shor, Co-founder & CEO of Medisafe, explores how Pharma companies can use digital therapeutics for advancing and supporting the patient journey, how new digital health tools are driving deeper...

Impetus Digital

Improving Drug Access with Data Analytics

Earlene Biggs, VP of Market Research & Analytics at ICON, explores best practices for life science market research and actionable analytics. She also shares her tips for creating organizational wellbeing...

Impetus Digital

- PMLiVE

Results released from new study of AstraZeneca’s COVID-19 antibody

A new study from Oxford University shows that Evusheld is effective in protecting against emerging Omicron variants

- PMLiVE

Pfizer/BioNTech COVID-19 vaccine produces strong immune response in children

A third dose of the vaccine has been trialled in children aged from six months to under five years old

- PMLiVE

AstraZeneca’s COVID-19 vaccine receives EMA approval for use as third-dose booster

Vaxzevria is a ‘viral vector’ vaccine, a technology that is also used to create vaccines for other infectious diseases like flu, HIV and Ebola

EU flag

EMA accepts Valneva’s marketing authorisation application for COVID-19 vaccine

The vaccine is currently the only inactivated, whole virus adjuvanted candidate in clinical trials in Europe

Innovative Medical Solutions for Postponing and Undoing Age-Related Disease

Aubrey de Grey, Chief Science Officer at SENS Research Foundation, discusses a range of interesting topics surrounding innovative interventions and technologies that could not just postpone, but theoretically reverse, age-related...

Impetus Digital

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links